课题基金 / 基金详情

Biomarkers of ANTidepressant RESponse : early indicators and novel targets

Biomarkers of ANTidepressant RESponse : early indicators and novel targets
抗抑郁药反应的生物标志物:早期指标和新目标
批准号:
407620
负责人:
Turecki Gustavo X
金额:
$8.17万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-06-01 至 2022-06-01

项目摘要

项目成果

Turecki Gustavo X的其他基金

相似基金

相关文献

中文摘要
翻译
抗抑郁药(AD)是目前治疗重度抑郁症(MDD)的最好方法,重度抑郁症是一种严重的精神障碍。阿尔茨海默病是西半球最常用的处方药之一,然而它们的试验和错误性质与有害的副作用相结合
英文摘要
Antidepressants (AD) are for now, the best treatment we have for major depression (MDD) a severe mental disorder. AD are one of the most commonly prescribed drugs in the western hemisphere, however their trial-and error nature combined with unwanted side-
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Extracellular vesicles (EVs) as a window into the depressed brain: an investigation of brain-cell derived EVs
Single-cell, high-throughput characterization of the depressed brain
Canada Research Chair - Tier 1
  • 批准号:
    481064
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2022
  • 负责人:
    Turecki Gustavo X
  • 依托单位:
Extracellular vesicles (EVs) as a window into the depressed brain: an investigation of brain-cell derived EVs
海外基金